Outcome of the Board Meeting held on Tuesday, 20th May, 2025 and submission of Audited Financial Results Standalone for the Fourth Quarter and year ended on 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Inject Kerala Limited's board, at its meeting on May 20, 2025, approved the audited standalone financial results for Q4 and full year ended March 31, 2025. Revenue from operations for FY25 stood at ₹1,904.58 lakh, a massive jump from ₹578.83 lakh in FY24 (roughly 229% growth). Profit after tax surged to ₹101.72 lakh from just ₹8.28 lakh last year, with basic EPS rising to ₹0.70 versus ₹0.07. Q4 revenue came in at ₹423.71 lakh with PAT of ₹7.32 lakh. Statutory auditor S. Mandawat & Co. issued an unmodified (clean) opinion on the results. The company operates in a single reportable segment - trading of vegetables.
A sharp financial turnaround with explosive revenue and profit growth, supported by a clean audit opinion, is a positive signal for shareholders. However, the balance sheet still shows accumulated losses (reserves of ₹-462.24 lakh), so investors should weigh the recovery against historical deficits.